Role of IL13RA2 in Sunitinib Resistance in Clear Cell Renal Cell Carcinoma
about
Sunitinib: the antiangiogenic effects and beyondInterleukin-16 rs4778889 polymorphism contributes to the development of renal cell cancer in a Chinese population.CCL2 as a potential therapeutic target for clear cell renal cell carcinoma.Interleukin-13 receptor α2 is associated with poor prognosis in patients with gastric cancer after gastrectomy.Interleukin-13 receptor alpha 2 cooperates with EGFRvIII signaling to promote glioblastoma multiforme.
P2860
Role of IL13RA2 in Sunitinib Resistance in Clear Cell Renal Cell Carcinoma
description
2015 nî lūn-bûn
@nan
2015年の論文
@ja
2015年論文
@yue
2015年論文
@zh-hant
2015年論文
@zh-hk
2015年論文
@zh-mo
2015年論文
@zh-tw
2015年论文
@wuu
2015年论文
@zh
2015年论文
@zh-cn
name
Role of IL13RA2 in Sunitinib Resistance in Clear Cell Renal Cell Carcinoma
@ast
Role of IL13RA2 in Sunitinib Resistance in Clear Cell Renal Cell Carcinoma
@en
type
label
Role of IL13RA2 in Sunitinib Resistance in Clear Cell Renal Cell Carcinoma
@ast
Role of IL13RA2 in Sunitinib Resistance in Clear Cell Renal Cell Carcinoma
@en
prefLabel
Role of IL13RA2 in Sunitinib Resistance in Clear Cell Renal Cell Carcinoma
@ast
Role of IL13RA2 in Sunitinib Resistance in Clear Cell Renal Cell Carcinoma
@en
P2093
P2860
P1433
P1476
Role of IL13RA2 in Sunitinib Resistance in Clear Cell Renal Cell Carcinoma
@en
P2093
Eijiro Nakamura
Hiromasa Sakamoto
Noboru Shibasaki
Noriaki Utsunomiya
Osamu Ogawa
Ryuichiro Arakaki
Takahiro Inoue
Tatsuaki Tsuruyama
Tomomi Kamba
Toru Kanno
P2860
P304
P356
10.1371/JOURNAL.PONE.0130980
P407
P577
2015-06-26T00:00:00Z